1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for Ireland Diabetes Drug Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in Ireland Diabetes Drug Market
4. Ireland Diabetes Drug Market by
Drug Type
4.1. Injectable Drugs
4.1.1. Insulin
4.1.2. Leraglutide
4.1.3. Aspart
4.1.4. Glargine
4.1.5. Exenatide
4.1.6. Pramlintide
4.2. Oral Drugs
4.2.1. Biguanides
4.2.2. Sulfonylureas
4.2.3. Meglitinides and D-phenylalanine
Derivatives
4.2.4. Thiazolidinediones
4.2.5. DPP-4 Inhibitors
4.2.6. Alpha-glucosidase
Inhibitors
5. Ireland Diabetes Drug Market by
Application
5.1. Type 1 Diabetes
5.2. Type 2 Diabetes
6. Company Profiles
6.1. Company 1
6.2. Company 2
6.3. Company 3
6.4. Company 4
6.5. Company 5
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for Ireland Diabetes Drug Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in Ireland Diabetes Drug Market
4. Ireland Diabetes Drug Market by
Drug Type
4.1. Injectable Drugs
4.1.1. Insulin
4.1.2. Leraglutide
4.1.3. Aspart
4.1.4. Glargine
4.1.5. Exenatide
4.1.6. Pramlintide
4.2. Oral Drugs
4.2.1. Biguanides
4.2.2. Sulfonylureas
4.2.3. Meglitinides and D-phenylalanine
Derivatives
4.2.4. Thiazolidinediones
4.2.5. DPP-4 Inhibitors
4.2.6. Alpha-glucosidase
Inhibitors
5. Ireland Diabetes Drug Market by
Application
5.1. Type 1 Diabetes
5.2. Type 2 Diabetes
6. Company Profiles
6.1. Company 1
6.2. Company 2
6.3. Company 3
6.4. Company 4
6.5. Company 5